Hepta
2 known investors
Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals. The platform uses transformer-based models with attention mechanisms to identify disease biomarkers from liquid biopsy samples.
AI & Machine LearningBiotechHealthtech
Investors · 2
In the news
- Chronic Disease Liquid Biopsy Startup Hepta Bio Raises $6.7M in Seed Financing | GenomeWebgenomeweb.com · 2025
- Illumina and Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insightsfinance.yahoo.com · 2025
- Hepta raises $6.7M to take liquid biopsy into liver diseaseendpoints.news · 2025
- Hepta Medical Raises €5.7M in Series A Fundingfinsmes.com · 2024
- Hepta Insights - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxntracxn.com · 2024
- Estonian tech company Hepta raises €2M to digitize energy infrastructure and automate inspectionweb.heptainsights.com · 2021